

## Antipsychotic Prior Authorization Form For Patients 18 Years or Older

Incomplete forms will not be reviewed

## Maryland Medicaid Office of Pharmacy Services

Phone: (833) 325-0105 Fax: (866) 440-9345

Patient Information	Date:						
Name:			DOB:		<b></b>	Л	□F
	Height:				BMI:	·	
Prescriber Information					, <u> </u>		
Name:		NPI:		S	pecialty:		
Contact Person Name:		Phor		one:		]	Fax:
	nostic and Statistical M						
□ ADHD □ Anti-Social or Borderline Personality Disorder □ Autism Spectrum Disorder □ Bipolar Disorder □ Conduct or Oppositional Defiant Disorder □ Dementia		☐ Generalized Anxiety Disord ☐ Intellectual Disability ☐ Major Depressive Disorder ☐ Obsessive Compulsive Disord ☐ Panic Disorder ☐ Psychotic Disorder – Not S		order			PTSD Schizoaffective Disorder Schizophrenia Social Phobia Sourette's Disorder Other Disorder (Specify):
	Т	Target Sympt	oms (please check	all that app	l ly)		
☐ Aggression ☐ Assault ☐ Delusion	☐ Depression ☐ Hallucinations ☐ Insomnia		☐ Irritability☐ Mania☐ Mood instabilit		☐ Self-Injurious Behaviors ☐ Other(s) (Specify):		
		Rec	quested Antipsych	otic			
Tier II Preferred			No	n-Preferred	Į		
☐ Vraylar ® ☐ Other:	□ Adasuve ®       □ m         □ Caplyta®       □ N         □ clozapine ODT       □ ol		☐ Lybalvi®☐ molindone☐ Nuplazid ®☐ olanzapine/fluoxetine☐ Rexulti ®		☐ Rykindo ® ☐ Saphris ® ☐ Secuado ® ☐ Uzedy ® ☐ Versacloz ®		☐ Zyprexa Relprevv ®☐ Other:
Dosage form:		Strength:	Strength:		Frequency:		Quantity:
Rationale of the request: _ Plan to discontinue or tape Is it a continuation of ther  Medication	er an antipsychotic for thi	is patient? Ple f Yes, Dischar		trials liant at least		No ontinu	ed
			☐ Yes ☐ I	No			
			☐ Yes ☐ I	No			
attest that:  ☐ Prescriber specialty: property of the benefits of antipsyrue and accurate to the bull of the request is for L.	nt evaluation and mon mia/diabetes, dyslipide vehotic treatment for the est of my knowledge.  ybalvi®: BMI ≥ 18 ar	itoring will l mia, weight is patient ou and the patie	be completed (e.g and/or CYP450 of atweigh the risks a nt has a past or of	. CMP/CBO lrug interact and verify the	C, baseline evitions).  That the information of olanzaping of olanzaping controls.	nation	provided on this form is
MDH and prescriber ack original signature for all p		_	-	-	-	, whic	h shall be considered as
Prescriber Signature:			Da	nte:			